171 related articles for article (PubMed ID: 12052214)
1. Duocarmycins--natures prodrugs?
Searcey M
Curr Pharm Des; 2002; 8(15):1375-89. PubMed ID: 12052214
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, chemical properties, and biological evaluation of CC-1065 and duocarmycin analogues incorporating the 5-methoxycarbonyl-1,2,9,9a-tetrahydrocyclopropa.
Boger DL; Hughes TV; Hedrick MP
J Org Chem; 2001 Apr; 66(7):2207-16. PubMed ID: 11281757
[TBL] [Abstract][Full Text] [Related]
3. The effect of a bromide leaving group on the properties of nitro analogs of the duocarmycins as hypoxia-activated prodrugs and phosphate pre-prodrugs for antitumor therapy.
Stevenson RJ; Denny WA; Ashoorzadeh A; Pruijn FB; van Leeuwen WF; Tercel M
Bioorg Med Chem; 2011 Oct; 19(20):5989-98. PubMed ID: 21920763
[TBL] [Abstract][Full Text] [Related]
4. Substituent effects within the DNA binding subunit of CBI analogues of the duocarmycins and CC-1065.
Boger DL; Stauffer F; Hedrick MP
Bioorg Med Chem Lett; 2001 Aug; 11(15):2021-4. PubMed ID: 11454471
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and evaluation of duocarmycin O-amino phenol prodrugs subject to tunable reductive activation.
Lajiness JP; Robertson WM; Dunwiddie I; Broward MA; Vielhauer GA; Weir SJ; Boger DL
J Med Chem; 2010 Nov; 53(21):7731-8. PubMed ID: 20942408
[TBL] [Abstract][Full Text] [Related]
6. Parallel synthesis and evaluation of 132 (+)-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (CBI) analogues of CC-1065 and the duocarmycins defining the contribution of the DNA-binding domain.
Boger DL; Schmitt HW; Fink BE; Hedrick MP
J Org Chem; 2001 Oct; 66(20):6654-61. PubMed ID: 11578217
[TBL] [Abstract][Full Text] [Related]
7. Metal cation complexation and activation of reversed CPyI analogues of CC-1065 and duocarmycin SA: partitioning the effects of binding and catalysis.
Ellis DA; Wolkenberg SE; Boger DL
J Am Chem Soc; 2001 Sep; 123(38):9299-306. PubMed ID: 11562212
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of a series of C3-substituted CBI analogues of CC-1065 and the duocarmycins.
Boger DL; Brunette SR; Garbaccio RM
J Org Chem; 2001 Jul; 66(15):5163-73. PubMed ID: 11463270
[TBL] [Abstract][Full Text] [Related]
9. The effect of sulfonate leaving groups on the hypoxia-selective toxicity of nitro analogs of the duocarmycins.
Ashoorzadeh A; Atwell GJ; Pruijn FB; Wilson WR; Tercel M; Denny WA; Stevenson RJ
Bioorg Med Chem; 2011 Aug; 19(16):4851-60. PubMed ID: 21767954
[TBL] [Abstract][Full Text] [Related]
10. Efficacious cyclic N-acyl O-amino phenol duocarmycin prodrugs.
Wolfe AL; Duncan KK; Parelkar NK; Brown D; Vielhauer GA; Boger DL
J Med Chem; 2013 May; 56(10):4104-15. PubMed ID: 23627265
[TBL] [Abstract][Full Text] [Related]
11. Chemical and biological explorations of the family of CC-1065 and the duocarmycin natural products.
Ghosh N; Sheldrake HM; Searcey M; Pors K
Curr Top Med Chem; 2009; 9(16):1494-524. PubMed ID: 19903166
[TBL] [Abstract][Full Text] [Related]
12. Selective treatment of cancer: synthesis, biological evaluation and structural elucidation of novel analogues of the antibiotic CC-1065 and the duocarmycins.
Tietze LF; Major F; Schuberth I; Spiegl DA; Krewer B; Maksimenka K; Bringmann G; Magull J
Chemistry; 2007; 13(16):4396-409. PubMed ID: 17455190
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of 1,2,8, 8a-Tetrahydrocyclopropa[c]pyrrolo[3,2-e]indol-4(5H)-one, the parent alkylation subunit of CC-1065 and the duocarmycins: impact of the alkylation subunit substituents and its implications for DNA alkylation catalysis.
Boger DL; Santillán A; Searcey M; Brunette SR; Wolkenberg SE; Hedrick MP; Jin Q
J Org Chem; 2000 Jun; 65(13):4101-11. PubMed ID: 10866627
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, DNA binding, and biological evaluation of water-soluble hybrid molecules containing two pyrazole analogues of the alkylating cyclopropylpyrroloindole (CPI) subunit of the antitumor agent CC-1065 and polypyrrole minor groove binders.
Baraldi PG; Balboni G; Pavani MG; Spalluto G; Tabrizi MA; Clercq ED; Balzarini J; Bando T; Sugiyama H; Romagnoli R
J Med Chem; 2001 Aug; 44(16):2536-43. PubMed ID: 11472207
[TBL] [Abstract][Full Text] [Related]
15. Novel analogues of CC-1065 and the duocarmycins for the use in targeted tumour therapies.
Tietze LF; Krewer B
Anticancer Agents Med Chem; 2009 Mar; 9(3):304-25. PubMed ID: 19275523
[TBL] [Abstract][Full Text] [Related]
16. Fundamental relationships between structure, reactivity, and biological activity for the duocarmycins and CC-1065.
MacMillan KS; Boger DL
J Med Chem; 2009 Oct; 52(19):5771-80. PubMed ID: 19639994
[No Abstract] [Full Text] [Related]
17. Duocarmycins, potent antitumor antibiotics produced by Streptomyces sp. structures and chemistry.
Yasuzawa T; Muroi K; Ichimura M; Takahashi I; Ogawa T; Takahashi K; Sano H; Saitoh Y
Chem Pharm Bull (Tokyo); 1995 Mar; 43(3):378-91. PubMed ID: 7774022
[TBL] [Abstract][Full Text] [Related]
18. Interconversion and stability of duocarmycins, a new family of antitumor antibiotics: correlation to their cytotoxic and antimicrobial activities in vitro.
Ichimura M; Ogawa T; Takahashi K; Mihara A; Takahashi I; Nakano H
Oncol Res; 1993; 5(4-5):165-71. PubMed ID: 8305742
[TBL] [Abstract][Full Text] [Related]
19. CBI-CDPBO1 and CBI-CDPBI1: CC-1065 analogs containing deep-seated modifications in the DNA binding subunit.
Boger DL; Yun W; Cai H; Han N
Bioorg Med Chem; 1995 Jun; 3(6):761-7. PubMed ID: 7582954
[TBL] [Abstract][Full Text] [Related]
20. Resolution of a CPzI precursor, synthesis and biological evaluation of (+) and (-)-N-Boc-CPzI: a further validation of the relationship between chemical solvolytic stability and cytotoxicity.
Baraldi PG; Cacciari B; Romagnoli R; Spalluto G; Boyce CW; Boger DL
Bioorg Med Chem Lett; 1999 Nov; 9(21):3087-92. PubMed ID: 10560730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
